Register for updates

 
 

Medicine & Health
RSS Feed
Drug Candidate Stabilizes Essential Transport Mechanism in Nerve Cells
Tuesday, January 31, 2017 9:00:00 AM

NAP blocks formation of "tangles" that contribute to Alzheimer's disease, says TAU researcher

Tau is a key brain protein involved in Alzheimer's disease and other brain diseases. Aggregates of Tau known as "neurofibrillary tangles" have been associated with nerve cell death and cognitive decline.

An important new Tel Aviv University study published in Molecular Psychiatry pinpoints the mechanism harnessed by the drug candidate NAP to block the formation of these harmful neurofibrillary tangles. It facilitates the interaction of Tau with microtubules, the minitubes that serve as "train tracks" for essential movement of biological material in nerve cells.

"Abnormal Tau proteins form tangles that contribute to the progression of Alzheimer's disease," said Prof. Illana Gozes, who led the research for the study. "We showed here, for the first time, that the drug candidate NAP augmented microtubule movement in nerve cells. At the molecular level, NAP, a fragment of activity-dependent neuroprotective protein (ADNP), enhanced Tau-microtubule interactions that block the recruitment of Tau to the tangles observed in Alzheimer's disease and related disorders."

Prof. Gozes is the incumbent of the Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Head of the Elton Laboratory for Molecular Neuroendocrinology at TAU's Sackler Faculty of Medicine and a member of TAU's Adams Super Center for Brain Studies and the Sagol School of Neuroscience.

Stabilizing a neurobiological process

Prof. Gozes is responsible for discovering ADNP, a gene that is dysregulated in Alzheimer's. Mutations in ADNP that occur in pregnancy are a major cause of autism with intellectual disability.

"ADNP and NAP operate through the stabilization of microtubules — tubes within the cell that maintain cellular shape," Prof. Gozes said. "They transport biological material. These microtubules break down in in Alzheimer's disease and may be dysfunctional in autism. NAP works to protect the microtubules, thereby protecting the cell."

"We now discovered that ADNP dramatically enhances Tau binding to the microtubules, protecting them against destruction and against Tau pathology. We further discovered that this action of ADNP is through its NAP fragment, which is now intended for further clinical development."

"Knowing the precise mechanism of its action, it will be much easier to bring NAP to the clinic and to patients," said Prof. Gozes. "Furthermore, the precise mechanism defines a new drug target for autism spectrum disorders, Alzheimer's disease and many other neurodegenerative and neuropsychiatric diseases."

The research for the study was conducted by TAU graduate students Yanina Ivashko-Pachima and Dr. Anna Malishkevich, together with Dr. Laura C. Sayas of Centro de Investigaciones Biomédicas de Canarias. NAP (now called CP201), a Tel Aviv University technology under a term sheet agreement with Coronis Neurosciences, is now planned for future clinical trials in patients with autism, specifically those with ADNP-related syndrome.




Latest News

Anti-Inflammatory, Anti-Stress Drugs Taken Prior to Surgery May Reduce Metastatic Recurrence

The body's stress inflammatory response is an active agent of cancer metastasis, TAU researchers say.

Cultural Activities May Influence the Way We Think

A new learning model may explain how culture helped shape human cognition and memory, TAU researcher says.

Marine Vessels are Unsuspecting Hosts of Invasive Species

Half of the ships passing along the Mediterranean coast of Israel carry damaging ascidians, TAU researchers say.

Inauguration of Steinhardt Museum of Natural History Celebrated at TAU on June 26

Historic event held in presence of philanthropist Michael Steinhardt and family, TAU governors, board members and faculty.

Baxter, Ramot at TAU and Tel Aviv Sourasky Medical Center Partner to Bring New Surgical Innovations Worldwide

Agreements will explore potential applications of promising early-stage research in areas of unmet need.

3,000-Year-Old Textiles Are Earliest Evidence of Chemical Dyeing in The Levant

Discovery provides insight into society and copper production in the Timna region at the time of David and Solomon, TAU researchers say.

Zuckerman Scholar Launches State-of-the-Art Laser Laboratory at TAU

Dr. Ishay Pomerantz hopes to lower the cost and size of particle accelerators for more practical social applications.

The Brain Mechanism Behind Multitasking

The brief reactivation of a learned memory can block interference from competing tasks, TAU researchers say.

DNA Delivery Technology Joins Battle Against Drug-Resistant Bacteria

New tool is major milestone against lethal condition, TAU researchers say.

Cardiac Stem Cells from Heart Disease Patients May Be Harmful

TAU researchers discover molecular pathway involved in toxic interaction between host cells and immune system.

Multispectral Imaging Reveals Ancient Hebrew Inscription Undetected for Over 50 Years

Military correspondence from the First Temple period discovered on reverse side of well-studied artifact at The Israel Museum, TAU researchers say.

Earliest Human Impact on the Environment Took Place 11,500 Years Ago

The earliest geological indication of humans' impact on the environment discovered in the Dead Sea, TAU researchers say.

IDEAS Immersion Program to Host Nine Female Entrepreneurs from TAU

Acceleration program partners with Cross Campus and Google to help budding women entrepreneurs incubate startups.

contentSecondary
c

© 2017 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University